Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2025-12-27 @ 5:36 AM
Study NCT ID:
NCT05201066
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-16
First Post:
2022-01-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-13
Start Date Type:
ACTUAL
Primary Completion Date:
2028-02-14
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02-14
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-03
First Submit QC Date:
None
Study First Post Date:
2022-01-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-13
Last Update Post Date:
2025-09-16
Last Update Post Date Type:
ESTIMATED